Inozyme Pharma (INZY)
(Delayed Data from NSDQ)
$5.81 USD
-0.02 (-0.34%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $5.82 +0.01 (0.17%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.81 USD
-0.02 (-0.34%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $5.82 +0.01 (0.17%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Zacks News
Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Inozyme Pharma, Inc. (INZY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Earnings Season Could Be Great for Inozyme (INZY)
by Zacks Equity Research
Inozyme (INZY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) fourth-quarter top line.
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study
by Zacks Equity Research
Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.
bluebird (BLUE) Up 101% in the Past Three Months: Here's Why
by Zacks Equity Research
bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.
Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment
by Zacks Equity Research
Aeglea BioTherapeutics (AGLE) seeks a nod for its lead candidate, pegzilarginase, for treating ARG1-D in the European Union. Stock surges post announcement.
bluebird's (BLUE) Gene Therapy Gets FDA Nod for Beta-Thalassemia
by Zacks Equity Research
bluebird's (BLUE) Zynteglo gets FDA-approval for transfusion-dependent beta-thalassemia in adult and pediatric patients. The stock gains.
Artelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical Study
by Zacks Equity Research
Artelo Biosciences (ARTL) reports positive pre-clinical data from one of its FABP5 inhibitors in anxiety-related disorders. Stock up.
Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal
by Zacks Equity Research
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline
How Much Upside is Left in Inozyme Pharma, Inc. (INZY)? Wall Street Analysts Think 309%
by Zacks Equity Research
The consensus price target hints at a 308.5% upside potential for Inozyme Pharma, Inc. (INZY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Inozyme Pharma, Inc. (INZY) Could Rally 257%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 256.5% in Inozyme Pharma, Inc. (INZY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.